MYCN amplification in neuroblastoma: A paradigm for the clinical use of an oncogene |
| |
Authors: | Manfred Schwab |
| |
Institution: | (1) Division of Cytogenetics - 0825, German Cancer Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany |
| |
Abstract: | Increase of the dosage of cellular oncogenes by DNA amplification is a frequent genetic alteration of cancer cells. The presence
of amplified cellular oncogenes is usually signalled by conspicuous chromosomal abnormalities, “double minutes” (DMs) or “homogeneously
staining chromsomal regions” (HSRs). Some human cancers carry a specific amplified oncogene at high incidence. In neuroblastomas
the amplification of MYCN has been found associated with aggressively growing cancers and is an indicator for poor prognosis.
MYCN amplification is of predictive value for identifying neuroblastoma patiens that require specific therapeutic regimens
and for identifying patients that will not benefit from chemotherapy.
This has been a lecture presented on a Tempus-course (S-JEP 11198–96) “Harmonization of Ph. D. degree to EU standards” |
| |
Keywords: | neuroblastoma N-Myc prediction therapy |
本文献已被 PubMed SpringerLink 等数据库收录! |